Dogwood Therapeutics’ (DWTX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Dogwood Therapeutics (NASDAQ:DWTX) in a research note published on Friday morning,Benzinga reports. The firm currently has a $12.00 target price on the stock.

Other equities research analysts have also issued reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Monday, December 22nd. Wall Street Zen lowered shares of Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Dogwood Therapeutics currently has an average rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Trading Up 0.7%

Shares of NASDAQ DWTX opened at $2.93 on Friday. The stock has a market cap of $6.71 million, a price-to-earnings ratio of -0.12 and a beta of 1.88. Dogwood Therapeutics has a 1-year low of $2.60 and a 1-year high of $14.69. The stock’s 50-day moving average is $3.62 and its 200 day moving average is $4.93.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new stake in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics as of its most recent SEC filing. Institutional investors own 9.05% of the company’s stock.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.